本帖最后由 老马 于 2012-1-13 21:20 编辑 # Q. F& e# B. L
7 W9 a; f! c. I" A! L3 W6 l爱必妥和阿瓦斯丁的比较1 a' e4 @8 A8 f9 l6 ~ h
$ H5 |& U Z/ y( v. h" b
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
! U6 V) d' O- F& \& x) W& a5 l" }3 G$ A9 ?
! g: [# J# Z5 {4 K7 M5 ^9 H$ h
9 H1 `9 l5 {& H* q- z% j K( s- j* [http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 v3 d4 z: N; J- j4 I==================================================9 B3 N6 H; c& W, T
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ f: c: a- z( L/ b2 I$ mPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 ]. T+ E3 `3 C# nResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported., s# @# k2 L% m! U) ~7 o1 ?
|